National Practice Guideline · Knee
Shounuck Patel, DO, Co-Author of the 2026 AAPM&R Guidance Statement on Platelet-Rich Plasma for Knee Osteoarthritis
The guideline: AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R. 2026.
Platelet-rich plasma, or PRP, is increasingly used to treat knee osteoarthritis, but not all PRP treatments are the same.
In 2026, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) published a new guidance statement on PRP for knee osteoarthritis in PM&R. Dr. Shounuck Patel was a co-author and member of the 11-physician Technical Expert Panel that developed the statement. [1]
The panel reviewed research through June 2025 and used a modified Delphi consensus process to establish five evidence-based recommendations and 11 consensus-based best practices.
The goal was to answer some of the most important questions surrounding PRP for knee arthritis:
The result is a more rigorous framework for using PRP as part of evidence-based knee osteoarthritis care. [1]
The panel gave a Grade A recommendation to consider intra-articular PRP for patients with mild to moderate knee osteoarthritis who continue to have symptoms despite conservative treatment. [1]
This means PRP should be considered as part of a broader treatment strategy rather than as a replacement for the fundamentals of knee osteoarthritis care, including:
The guidance also emphasizes treating the individual patient rather than using age alone to determine candidacy.
Current evidence does not establish a definitive:
As a best practice, the panel concluded that treating knee osteoarthritis earlier in the disease process may lead to better outcomes.
An active infection is a contraindication to a joint injection.
Patients with active malignancy or a history of malignancy in remission require additional consideration. The guidance recommends consultation with the patient’s treating oncology team.
Other medical conditions may influence outcomes without automatically excluding a patient from PRP treatment.
Comprehensive
Yes.
One of the most important contributions of the new AAPM&R guidance is its emphasis on the actual platelet dose delivered to the knee.
The panel recommends a total platelet dose of at least:
for improved long-term clinical outcomes. [1]
This is important because PRP is not a standardized medication.
Different PRP preparation systems can produce very different:
Two treatments may both be called “PRP” while delivering very different biological products.
For patients and clinicians, this means the question should not simply be:
A more meaningful question is:
Current evidence does not establish that one is clearly superior.
Both leukocyte-poor PRP and leukocyte-rich PRP have demonstrated clinical benefit in knee osteoarthritis. [1]
The guidance therefore does not conclude that leukocyte-poor PRP should automatically be preferred over leukocyte-rich PRP.
The panel does recommend minimizing red blood cell contamination. However, direct clinical evidence showing exactly how residual red blood cells affect patient outcomes remains limited.
The guidance supports ultrasound guidance rather than landmark guidance for intra-articular PRP injections of the knee.
Ultrasound allows the physician to visualize the joint and confirm needle placement. Evidence involving knee injections has demonstrated greater accuracy with ultrasound guidance.
For PRP, where preparation and dosing matter, accurate delivery is an important part of the overall treatment process.
When a knee effusion is present, the panel recommends considering aspiration of the joint fluid before PRP injection.
An effusion is an abnormal buildup of fluid inside the knee joint.
Removing excess fluid before injecting PRP may allow the physician to more precisely deliver the intended treatment into the joint.
The panel recommends considering avoidance of intra-articular local anesthetic because of concerns about potential toxicity to cartilage cells and platelets.
At the same time, the guidance acknowledges that direct clinical outcome evidence in this specific setting remains limited.
This is an example of an area where laboratory evidence and expert consensus inform clinical practice, even though definitive clinical trial data are not yet available.
There is no established rule that every patient should receive a predetermined series of PRP injections.
The guidance recommends evaluating the patient’s response after the initial treatment before deciding whether additional injections are appropriate. [1]
Evidence comparing single versus multiple PRP injections remains inconsistent.
This means that automatically selling every patient a package of multiple injections is not necessarily supported by the available evidence.
Treatment should instead be individualized based on:
Comprehensive
One of the strengths of the AAPM&R guidance is that it clearly identifies what remains uncertain.
Evidence is still insufficient or inconsistent regarding:
Several recommendations involving:
Based on current evidence, PRP should not be described as a proven method of regenerating cartilage or reversing knee osteoarthritis.
Patients may experience improvement in:
But symptomatic improvement is not the same as structural cartilage regeneration.
The panel specifically called for standardized, dose-dependent randomized trials that evaluate both structural outcomes and symptomatic outcomes. [1]
This distinction is fundamental to responsible orthobiologic medicine.
Evidence that PRP can reduce pain and improve function is not the same as evidence that PRP rebuilds an arthritic knee joint.
The guidance makes an important distinction between standard intra-articular PRP and treatment that also addresses the subchondral bone.
Evidence is insufficient to recommend routine intra-articular PRP alone for severe knee osteoarthritis.
However, for selected patients with severe osteoarthritis and MRI evidence of clinically relevant subchondral bone involvement, the panel gave a Grade A recommendation that:
[1]
Intraosseous PRP involves treating the bone beneath the joint surface in addition to injecting PRP into the knee joint itself.
This is an advanced procedure that requires specialized training and should not be confused with a standard intra-articular knee injection.
PRP should not be used simply as a way to avoid surgery regardless of the severity of osteoarthritis.
The AAPM&R guidance explicitly recognizes surgical arthroplasty as an appropriate alternative for advanced bone-on-bone osteoarthritis that has not responded adequately to nonsurgical treatment. [1]
For a patient with:
This becomes particularly important when a patient already meets accepted indications for arthroplasty.
Contemporary arthroplasty guidance also supports proceeding with surgery without requiring patients who have already failed appropriate nonoperative treatment to undergo additional mandatory treatments simply to delay replacement. [2]
The goal should therefore not be to frame PRP and knee replacement as competing philosophies.
The better question is:
Based on the new guidance, useful questions include:
These questions help shift the conversation away from whether PRP simply “works” and toward whether the treatment is being selected, prepared, and delivered appropriately.
As a co-author of the 2026 AAPM&R guidance statement, Shounuck Patel, DO, contributed to a national effort to improve standardization, transparency, and evidence-based patient selection for PRP treatment of knee osteoarthritis.
The guidance provides a more nuanced message than either:
“PRP works.”
or
“PRP does not work.”
Instead, it identifies:
For patients considering PRP for knee osteoarthritis, the most useful question is therefore not simply whether PRP is “regenerative.”
It is:
The strongest evidence supports intra-articular PRP for patients with mild to moderate knee osteoarthritis who remain symptomatic despite conservative treatment. [1]
The AAPM&R panel recommends a total platelet dose of at least 10 billion platelets to improve long-term clinical outcomes. [1]
Current evidence does not establish that one is superior. Both leukocyte-poor and leukocyte-rich PRP may be considered. [1]
The guidance supports ultrasound guidance rather than landmark guidance because ultrasound improves injection accuracy.
There is no universally established number. The panel recommends evaluating the patient’s response to the first injection before deciding whether additional treatments are appropriate. [1]
Current evidence does not establish PRP as a proven method of regenerating cartilage or reversing osteoarthritis. PRP may improve pain and function, but structural cartilage restoration should not be expected based on current evidence. [1]
Routine intra-articular PRP alone is not supported by sufficient evidence for severe osteoarthritis. In selected patients with severe OA and clinically correlating MRI evidence of subchondral bone involvement, intraosseous PRP may be considered in addition to intra-articular PRP. [1]
No. For advanced bone-on-bone osteoarthritis with persistent pain and functional limitation despite appropriate nonsurgical treatment, knee replacement remains an appropriate treatment option. [1]
Dr. Shounuck Patel, DO is a leader in the field of orthopedic regenerative medicine.
Find out if you are a Regenerative Medicine candidate. We service Los Angeles County, Orange County, San Diego County and beyond. For more information contact our patient concierge at in**@***********er.com or call us at (310) 929-9790.